🇺🇸 FDA
Patent

US 11590135

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

granted A61KA61K31/513A61P

Quick answer

US patent 11590135 (Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists) held by Corcept Therapeutics Incorporated expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/513, A61P, A61P1/16